Illumina ( ILMN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.6%. By the end of trading, Illumina rose 24 cents (0.6%) to $39.56 on light volume. Throughout the day, 993,595 shares of Illumina exchanged hands as compared to its average daily volume of three million shares. The stock ranged in a price between $39.03-$39.72 after having opened the day at $39.10 as compared to the previous trading day's close of $39.32. Other companies within the Health Care sector that increased today were: Biostar Pharmaceuticals ( BSPM), up 37.4%, Chelsea Therapeutics International ( CHTP), up 16.7%, Dendreon ( DNDN), up 13.8%, and Peregrine Pharmaceuticals ( PPHM), up 13.6%. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $4.75 billion and is part of the drugs industry. The company has a P/E ratio of 58.8, above the average drugs industry P/E ratio of 57.9 and above the S&P 500 P/E ratio of 17.7. Shares are up 34.4% year to date as of the close of trading on Tuesday. Currently there are seven analysts that rate Illumina a buy, one analyst rates it a sell, and 10 rate it a hold. TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and premium valuation.